Cardiff Oncology (CRDF) Other Non-Current Liabilities (2011 - 2021)
Cardiff Oncology (CRDF) posted Other Non-Current Liabilities of $30000.0 for Q3 2021, down 85.98% sequentially from $214000.0 in Q2 2021, and down 66.08% YoY from $88452.0 in Q3 2020.
Cardiff Oncology (CRDF) Other Non-Current Liabilities (2011 - 2021) Analysis & Trends
Cardiff Oncology has reported Other Non-Current Liabilities for 11 years, with the latest figure at $30000.0 in Q3 2021.
- Quarterly Other Non-Current Liabilities fell 66.08% year-over-year to $30000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $30000.0 (down 66.08% YoY) and the FY2020 annual result came in at $285000.0, up 7025.0% from the prior year.
- Other Non-Current Liabilities eased to $30000.0 in Q3 2021 per CRDF's latest filing, from $214000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $2.0 million in Q3 2017 and troughed at $2020.0 in Q1 2020.
- A 5-year average of $268761.7 and a median of $72701.0 in 2020 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2018 and 2020: Other Non-Current Liabilities sank 96.55% in 2018, then jumped 7025.0% in 2020.
- Over 5 years, Other Non-Current Liabilities stood at $649387.0 in 2017, then plunged by 95.02% to $32315.0 in 2018, then sank by 87.62% to $4000.0 in 2019, then surged by 7025.0% to $285000.0 in 2020, then tumbled by 89.47% to $30000.0 in 2021.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $30000.0, $214000.0, and $78000.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 30,000.00 |
| Jun 30, 2021 | 214,000.00 |
| Mar 31, 2021 | 78,000.00 |
| Dec 31, 2020 | 285,000.00 |
| Sep 30, 2020 | 88,452.00 |
| Jun 30, 2020 | 72,701.00 |
| Mar 31, 2020 | 2,020.00 |
| Dec 31, 2019 | 4,000.00 |
| Sep 30, 2019 | 4,956.00 |
| Jun 30, 2019 | 18,287.00 |
| Mar 31, 2019 | 42,076.00 |
| Dec 31, 2018 | 32,315.00 |
| Sep 30, 2018 | 70,347.00 |
| Jun 30, 2018 | 67,847.00 |
| Mar 31, 2018 | 779,076.00 |
| Dec 31, 2017 | 649,387.00 |
| Sep 30, 2017 | 2.04 Mn |
| Jun 30, 2017 | 350,862.00 |
| Mar 31, 2017 | 279,434.00 |
| Dec 31, 2016 | 834,940.00 |